{
    "nct_id": "NCT04862650",
    "official_title": "A Phase II Trial of the Efficacy and Safety of the Combination of Cemiplimab and Low-Dose Paclitaxel and Carboplatin in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck",
    "inclusion_criteria": "* Recurrent/metastatic (R/M) SCCHN of the oral cavity, oropharynx, larynx and hypopharynx\n* No prior systemic therapy for treatment of R/M disease\n* Patients with squamous cell carcinoma of an unknown primary are eligible provided their tumor tested positive for p-16 and they have previously received treatment for locoregional head and neck cancer\n* Must be at least four weeks since prior radiation and/or surgery\n* Must be at least four weeks from curative intent systemic therapy. Of note: patients who have received up to two courses of chemoradiotherapy (CRT) for locoregionally advanced disease are eligible. Induction chemotherapy will not be considered a separate line of therapy\n* At least one measurable lesion as defined by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 on screening computed tomography (CT) or magnetic resonance imaging (MRI)\n* 18 years of age and older\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n* White blood cell (WBC) count > 2,500 cells/uL\n* Absolute neutrophil count (ANC) >1,500 cells/uL\n* Platelet count >= 100,000 cells/uL\n* Hemoglobin >= 9 g/dL\n* Creatinine =< 1.6 mg/dL\n* Total bilirubin =< 1.6 mg/dL\n* Serum glutamic oxaloacetic transaminase (SGOT) (aspartate transaminase [AST]), serum glutamic-pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) =< 2.5 x upper limit of normal (ULN)\n* Potassium >= lower limit of normal (LLN)\n* Willingness to use medically acceptable contraception throughout the study period and four months after the final administration of treatment\n* For female subjects with reproductive potential: a negative serum pregnancy test at baseline\n* Ability and willingness to provide written informed consent and to comply with the study visits and assessment schedule\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Disease amenable to curative local therapy\n* Nasopharyngeal, salivary gland, lip, or sinonasal carcinoma\n* Disease that requires corticosteroids or other ongoing immunosuppressive treatment\n* Previous treatment with mAb-based immunotherapy for treatment of prior oncologic treatment\n* Previous treatment with PI3K inhibitors\n* Known brain metastases, unless stable for at least 21 days prior to registration\n* Known infection human immunodeficiency virus (HIV), hepatitis B or C\n* Clinically significant cardiac disease (e.g., congestive heart failure, unstable or uncontrolled angina, myocardial infarction) within the past six months\n* History of pneumonitis within the past five years\n* Recipient of live vaccines (including attenuated) within 30 days of planned study treatment\n* Female patients who are pregnant or breast-feeding\n* Any other condition or circumstance that could interfere with adherence to the study's procedures or requirements or otherwise compromise the study's objectives in the opinion of the Principal Investigator",
    "miscellaneous_criteria": ""
}